Trial · NCT01996969
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
NCT01996969, Not applicable, Completed, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer. Trials, record NCT01996969. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01996969
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
- NCT number
- NCT01996969
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 117 participants, actual
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Regorafenib
- First posted
- 2013-11-27
- Last updated
- 2019-02-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Predictive biomarker in terms of disease control rate | 1 year | This study aims at identifying potential molecular subgroup of colorectal cancer that may benefit from regorafenib treatment in terms of disease control rate. |
| Secondary | Disease control rate | 1 year | Disease control rate in all treated population |
| Secondary | Progression-free survival | 1 year | Progression-free survival in all treated population |
| Secondary | Overall survival | 1 year | Overall survival in all treated population |
| Secondary | number of participants with adverse events | 1 year | adverse events according to NCI-CTCAE v.4.0 |
| Secondary | Progression-free survival according to biomarker status | 1 year | Progression-free survivals will be compared according to biomarker status |
| Secondary | Overall survival according to biomarker status | 1 year | Overall survivals will be compared according to biomarker status |
| Secondary | Assessment of adequate response evaluation modality after regorafenib treatment | 1 year | Changes in size, CT attenuation (HFU) and PET metabolism (SUV) will be evaluated and assessed in relation to survival outcomes |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01996969
GET https://conductscience.org/api/trials/v1/NCT01996969/registered